EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease

Daniel Martin Simadibrata iD, Elvira Lesmana, Ronnie Fass

Journal of Gastroenterology and Hepatology · 2024-05 · 39 (5) · 796-805

DOI: 10.1111/jgh.16475 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 23.01.2024. Verfasst von Daniel Martin Simadibrata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Pyrroles, Gastroesophageal Reflux, Sulfonamides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Up to 40% of gastroesophageal reflux disease (GERD) patients experience inadequate symptom relief with a proton pump inhibitor (PPI), termed PPI‐resistant or refractory GERD. Vonoprazan, a potassium‐competitive acid blocker, has better efficacy than PPI in suppressing gastric acid secretion. This meta‐analysis summarizes the efficacy and safety of vonoprazan for treating PPI‐resistant GERD (both erosive esophagitis [EE] and non‐erosive reflux disease [NERD]).

Methods

Four electronic databases (Medline, Embase, SCOPUS, and CENTRAL) were searched for studies indexed until August 1, 2023. Both observational studies and clinical trials assessing the efficacy and safety of vonoprazan in PPI‐resistant GERD were included. Efficacy outcomes included healing and maintenance rates of EE and improvement of the Frequency Scale for Symptoms of GERD (FSSG) scores. Serious adverse events (SAEs) were considered a safety outcome. The modified Newcastle‐Ottawa Scale (NOS) was used to assess study quality.

Results

Twelve studies were included in this meta‐analysis. Healing rates of PPI‐resistant EE with vonoprazan 20 mg were 91.7% (95% CI 86.8–94.8%) and 88.5% (95% CI 69.7–96.2%) at weeks 4 and 8, respectively. For healed PPI‐resistant EE, the overall maintenance rates with vonoprazan 10 mg were 82.6% (95% 61.2–95.0%) at week 8, 86.0% (95% CI 72.1–94.7%) at week 24, and 93.8% (95% CI 69.8–99.8%) at week 48. FSSG scores were improved in 74.6% (95% CI 65.8–81.7%) and 51.9% (95% CI 37.8–65.7%) of patients at weeks 4 and 8. Overall, no SAE was reported.

Conclusion

Vonoprazan demonstrated high efficacy in the healing and maintenance of PPI‐resistant EE and moderate efficacy for the improvement of FSSG score. Vonoprazan was well tolerated in PPI‐resistant GERD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsPyrrolesGastroesophageal RefluxSulfonamidesDrug ResistanceHumansTreatment Outcome

Stichwörter der Autor:innen

Gastroesophageal reflux diseaseMeta‐analysisPPI‐resistant GERDRefractory GERDvonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineProton Pump InhibitorsPyrrolesSulfonamides

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Division of Gastroenterology and Hepatology, MetroHealth Medical System, Case Western Reserve University, Cleveland, OH, USA.

ORCID-Profile: Daniel Martin Simadibrata

Zitieren

APA

Simadibrata, D. M., Lesmana, E., & Fass, R. (2024). A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease. Journal of Gastroenterology and Hepatology, 39(5), 796-805. https://doi.org/10.1111/jgh.16475

Vancouver

Simadibrata DM, Lesmana E, Fass R. A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease. Journal of Gastroenterology and Hepatology. 2024;39(5):796-805. doi:10.1111/jgh.16475

BibTeX
@article{Simadibrata2024,
  author = {Simadibrata, Daniel Martin and Lesmana, Elvira and Fass, Ronnie},
  title = {A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {5},
  pages = {796--805},
  doi = {10.1111/jgh.16475}
}
Kostenlos starten →